Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors

NCT05329103 is registered in ClinicalTrials.gov with Peel Therapeutics Inc as lead sponsor.

NCT NCT05329103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05329103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors
Lead sponsor
Peel Therapeutics Inc
Phase
Phase 1
Overall status
Recruiting
Start date
July 11, 2022
Completion date
October 31, 2026
Enrollment
65 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor